|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Headache: The Journal of Head and Face PainVolume 34 Issue 9, Pages 497 - 502 Published Online: 18 May 2005 © 2010 American Headache Society Published on behalf of the American Headache Society
Abstract | Full Text: PDF (Size: 198K) | Related Articles | Citation Tracking  Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine Copyright © 1994 American Headache Society (formerly the American Association for the Study of Headache) KEYWORDS Fluoxetine • chronic daily headache • migraine • double-blind stud ABSTRACTSYNOPSIS This study is the first double-blind placebo-controlled trial of fluoxetine for chronic daily headache (CDH) and migraine. After a one month single-blind baseline on placebo, subjects with CDH (n=64) and migraine (n=58) were randomly assigned to a three month trial of fluoxetine (20 mg) or an identical placebo. Fluoxetine and placebo were increased to 40 mg in the second month, depending on patient response. Patients kept daily headache records, and completed 100 mm visual analogue scales (VAS) of headache and mood each month. For the group of CDH patients on fluoxetine, overall headache status (VAS) after three months compared to the end of the single-blind placebo baseline improved a mean of 50% vs. 11% for those receiving the double-blind placebo ( P =.029), with 47% vs. 23% improving at least 50% ( P =.097, n.s.). Fluoxetine patients showed significant improvement in monthly mood ratings compared to placebo (.001 by the end of the study), and modest but significant improvement in daily records of headache frequency ( P =.019) but not pain severity. Significant mood improvements preceded improvement in headache, reaching significance by the end of the second month on fluoxetine ( P =.013), while headache improvement emerged only during the third month ( P =.001). Double-blind investigator judgement identified more headache improvement in fluoxetine than placebo recipients (40% vs. 22%, P =.032). Fluoxetine was not effective on any measure for migraine, with the exception of modest mood improvement at the end of the third month ( P =.043). Adverse effects were more frequent but not more severe for fluoxetine, including sleep disturbance (28% vs. 8%, P =.008), tremors (20% vs. 5%, P =.025), and minor stomach pain (13% vs. 0%, P =.008). Fluoxetine appears moderately effective for CDH but not migraine, with a generally tolerable side effect profile. The influence on headache may be linked to its effect on mood. In general, study subjects were not clinically depressed. Future research might focus on subjects with comorbid depression and headache. Accepted for publication March 26, 1994 | 
|
